Monday, August 29, 2022

Pharmacological Madness

Madness, I tell you.

Aug 22 (Reuters) - Pfizer Inc (PFE.N) and German partner BioNTech said on Monday they had sought U.S. authorization for a COVID-19 vaccine booster retooled to target the Omicron variant, and would have doses available to ship immediately after regulatory clearance.

Note that the FDA has said they will not require separate studies on this formulation, much as is the case for annual flu shots.

That's nuts.

We already know the existing formulation is dangerous and damages immune response generally, meaning it is likely more harmful than protective, particularly given its rapid waning of effectiveness -- and this is giving the data the best slant available for the jabs.